Rausch, M.; Weiss, A.; Zoetemelk, M.; Piersma, S.R.; Jimenez, C.R.; van Beijnum, J.R.; Nowak-Sliwinska, P.
Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance. Cancers 2020, 12, 3172.
https://doi.org/10.3390/cancers12113172
AMA Style
Rausch M, Weiss A, Zoetemelk M, Piersma SR, Jimenez CR, van Beijnum JR, Nowak-Sliwinska P.
Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance. Cancers. 2020; 12(11):3172.
https://doi.org/10.3390/cancers12113172
Chicago/Turabian Style
Rausch, Magdalena, Andrea Weiss, Marloes Zoetemelk, Sander R. Piersma, Connie R. Jimenez, Judy R. van Beijnum, and Patrycja Nowak-Sliwinska.
2020. "Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance" Cancers 12, no. 11: 3172.
https://doi.org/10.3390/cancers12113172
APA Style
Rausch, M., Weiss, A., Zoetemelk, M., Piersma, S. R., Jimenez, C. R., van Beijnum, J. R., & Nowak-Sliwinska, P.
(2020). Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance. Cancers, 12(11), 3172.
https://doi.org/10.3390/cancers12113172